報價延遲最少15分鐘:2025/07/18 16:30 EDT
盤後時段
|
||||
|
-- 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
18.68
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-6.20/-7.33
|
|
企業價值
150.03M
|
| 資產負債 |
|
每股賬面淨值
3.55
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
28.52M
|
|
每股收益
11.82
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/07/18 16:30 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program. |
